Physician profile
Charles Ronan
NPI 1639696057
$9,148.84
in general payments reported to CMS, 2019-2025
27 companies · $1,701 in 2025
The $1,701 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $689 · 2021: $1,366 · 2022: $1,602 · 2023: $757 · 2024: $1,591 · 2025: $1,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,024 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,024.03 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,262.46 | 2019-2025 | Simbrinza, Rhopressa, Rocklatan |
| New World Medical,INC. | $1,046.82 | 2020-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Glaukos Corporation | $895.41 | 2020-2025 | Idosetr, Istent Infinite, Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $584.14 | 2019-2021 | |
| Harrow Eye, LLC | $573.96 | 2023-2025 | Vevye |
| Bausch & Lomb Americas INC. | $513.97 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $453.34 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $446.15 | 2021-2025 | Oxervate |
| Rxsight INC | $385.54 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Novartis Pharmaceuticals Corporation | $369.33 | 2019-2023 | |
| Allergan, INC. | $265.46 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $255.96 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $252.57 | 2019-2021 | |
| Biotissue Holdings INC. | $227.46 | 2024 | |
| Ocular Therapeutix, INC. | $202.81 | 2021-2024 | Dextenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $193.75 | 2019 | |
| Sight Sciences, INC. | $192.34 | 2021-2022 | |
| Abbvie INC. | $181.22 | 2022-2024 | Durysta |
| The Cameron-Ehlen Group, INC. | $153.42 | 2020-2021 | |
| Ivantis, INC | $136.52 | 2019 | |
| Sun Pharmaceutical Industries INC. | $135.65 | 2019-2023 | Cequa |
| Ani Pharmaceuticals, INC. | $135.34 | 2025 | Purified Cortrophin Gel |
| Oyster Point Pharma, INC. | $134.59 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $53.67 | 2021-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Mallinckrodt Hospital Products INC. | $52.54 | 2021-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $23.54 | 2019 | |
| Astellas Pharma US INC | $20.88 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ronan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.